Glaukos Expands Retinal Pipeline with Exclusive License for Tri-Specific Biologic RO-104
Event summary
- Glaukos has secured an exclusive license for RO-104, a tri-specific biologic targeting nAMD, DME, DR, and RVO.
- The deal also grants Glaukos access to RevOpsis’ RevMod™ platform for up to four additional retinal biologic candidates.
- RO-104 is designed to block VEGF-A, VEGF-C, and Ang-2, showing superior preclinical efficacy compared to existing anti-VEGF therapies.
- Financial terms of the agreement were not disclosed.
The big picture
Glaukos is deepening its focus on retinal diseases, a strategic shift from its historical emphasis on glaucoma and corneal disorders. The deal with RevOpsis positions Glaukos to compete in a rapidly evolving retinal therapeutics market, where multi-specific biologics are gaining traction as next-generation treatments. The move underscores the industry’s push toward more targeted and efficient therapies for chronic retinal conditions.
What we're watching
- Clinical Validation
- How RO-104’s tri-specific mechanism will perform in human trials compared to existing anti-VEGF treatments.
- Pipeline Expansion
- The pace at which Glaukos leverages the RevMod platform to develop additional retinal candidates.
- Commercial Strategy
- Whether Glaukos can successfully integrate and commercialize RO-104 alongside its existing retinal portfolio.
